ClinicalTrials.gg
Drug

Capsaicin clinical trials

Also written Qutenza, ALGRX 4975, NGX-4010 and Zostrix.

Includes 1 study of Capsaicin palmitate.

studies test it
105
open now
14
in phase 3
25
first study started
1995

How each study uses Capsaicin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Capsaicin studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
16 Nov 2009 · QUTENZA · NDA 022395 (FDA, Drugs@FDA)
European Union
15 May 2009 · Qutenza · EMEA/H/C/000909 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Capsaicin
45
Capsaicin Dermal Patch
8
Capsaicin 8% Patch
5
Capsaicin patch
4
Intranasal capsaicin
3

Brand

Qutenza
17

Development codes

ALGRX 4975
5
NGX-4010
3
CTNX-4975
1
NGX-1998
1

Other names

Zostrix
2

Studies by the year they started

99 studies that test it; most in 2016 (9)

Studies that test Capsaicin, by start year
YearStudies
19951
19971
19981
20011
20021
20031
20043
20056
20063
20081
20093
20107
20115
20126
20135
20144
20153
20169
20176
20184
20197
20201
20213
20224
20233
20244
20254
20262

By phase

A phase 1/2 study counts in both.

Early Phase 1
9
Phase 1
13
Phase 2
33
Phase 3
25
Phase 4
17
No phase
17

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 31 · Other 74

NeurogesX (15) · University of Florida (5) · AlgoRx Pharmaceuticals (5) · The University of Texas Health Science Center, Houston (3) · Universitaire Ziekenhuizen KU Leuven (3) · Astellas Pharma Inc (3) · Aalborg University (2) · Institut Cancerologie de l'Ouest (2)

Often tested with

Tested in the same studies.

Diclofenac (2) · Anti-Inflammatory Agents, Non-Steroidal (2) · Cinnamaldehyde (2) · Flupirtine (1) · Saline Solution (1) · Sodium Chloride (1) · Transcutaneous Electrical Nerve Stimulation (1) · Lidocaine, Prilocaine Drug Combination (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 7, 1 in phase 3

Studies that test Capsaicin, phase 3 first.

Studies

Open first, then newest update. How each study uses Capsaicin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 105

See all 105 studies that test Capsaicin →

Given beside what is tested · 7 — Capsaicin is usual care or a partner of the new treatment
As the comparator · 3 — what is tested is compared with Capsaicin

Codes

What other systems call Capsaicin · ClinicalTrials.gg INT007136

  • MeSH (NLM) D002211CapsaicinConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) S07O44R1ZMCAPSAICINConfirmed FDA, NLM, Wikidata
  • RxNorm 1992Confirmed FDA, Wikidata
  • Wikidata Q273169capsaicinConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C339CapsaicinOne source FDA
  • DrugBank DB06774One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.